×
S&P 500   3,845.08
DOW   31,037.68
QQQ   288.80
S&P 500   3,845.08
DOW   31,037.68
QQQ   288.80
S&P 500   3,845.08
DOW   31,037.68
QQQ   288.80
S&P 500   3,845.08
DOW   31,037.68
QQQ   288.80
NASDAQ:ATHX

Athersys Stock Forecast, Price & News

$0.25
+0.01 (+4.21%)
(As of 07/6/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.24
$0.25
50-Day Range
$0.18
$0.76
52-Week Range
$0.18
$1.81
Volume
2.44 million shs
Average Volume
8.41 million shs
Market Capitalization
$65.38 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$0.25

Athersys MarketRank™ Forecast

Analyst Rating
Reduce
1.00 Rating Score
Upside/​Downside
0.9% Upside
$0.25 Price Target
Short Interest
Healthy
22.86% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.51mentions of Athersys in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.27) to ($0.23) Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

0.75 out of 5 stars

Medical Sector

1160th out of 1,433 stocks

Pharmaceutical Preparations Industry

559th out of 683 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive ATHX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Athersys and its competitors with MarketBeat's FREE daily newsletter.

Athersys logo

About Athersys (NASDAQ:ATHX) Stock

Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product, which is in Phase III clinical study for the treatment of patients suffering from neurological damage from an ischemic stroke, as well as for acute respiratory distress syndrome, trauma complications, HSC transplant support, and other indications. It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients, including those suffering from serious conditions with unmet medical needs. The company has license and collaboration agreements with Healios K.K. to develop and commercialize MultiStem cell therapy for ischemic stroke, acute respiratory distress syndrome, and ophthalmological indications, as well as for the treatment of liver, kidney, pancreas, and intestinal tissue diseases; and the University of Minnesota to develop MultiStem cell therapy platform. Athersys, Inc. was founded in 1995 and is headquartered in Cleveland, Ohio.

ATHX Stock News Headlines

Athersys (NASDAQ:ATHX) Coverage Initiated at StockNews.com
StockNews.com Initiates Coverage on Athersys (NASDAQ:ATHX)
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ATHX
Employees
104
Year Founded
1995

Company Calendar

Last Earnings
5/06/2022
Today
7/07/2022
Next Earnings (Estimated)
8/08/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$0.25
High Stock Price Forecast
$0.25
Low Stock Price Forecast
$0.25
Forecasted Upside/Downside
+0.9%
Consensus Rating
Reduce
Rating Score (0-4)
1
Research Coverage
1 Analysts

Profitability

Net Income
$-86,960,000.00
Pretax Margin
-981.52%

Debt

Sales & Book Value

Annual Sales
$5.51 million
Book Value
$0.07 per share

Miscellaneous

Free Float
225,511,000
Market Cap
$65.38 million
Optionable
Optionable
Beta
-1.29

Social Links















Athersys Frequently Asked Questions

Should I buy or sell Athersys stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Athersys in the last year. There are currently 1 sell rating for the stock. The consensus among Wall Street analysts is that investors should "sell" Athersys stock.
View analyst ratings for Athersys
or view top-rated stocks.

What is Athersys' stock price forecast for 2022?

1 Wall Street analysts have issued 12 month price targets for Athersys' shares. Their ATHX stock forecasts range from $0.25 to $0.25. On average, they predict Athersys' stock price to reach $0.25 in the next twelve months. This suggests a possible upside of 0.9% from the stock's current price.
View analysts' price targets for Athersys
or view top-rated stocks among Wall Street analysts.

How has Athersys' stock price performed in 2022?

Athersys' stock was trading at $0.9026 at the start of the year. Since then, ATHX stock has decreased by 72.6% and is now trading at $0.2477.
View the best growth stocks for 2022 here
.

When is Athersys' next earnings date?

Athersys is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022.
View our earnings forecast for Athersys
.

How were Athersys' earnings last quarter?

Athersys, Inc. (NASDAQ:ATHX) released its quarterly earnings results on Friday, May, 6th. The biopharmaceutical company reported ($0.09) earnings per share (EPS) for the quarter. The biopharmaceutical company had revenue of $2.91 million for the quarter.
View Athersys' earnings history
.

Who are Athersys' key executives?

Athersys' management team includes the following people:
  • Dr. John J. Harrington Ph.D., Co-Founder, Chief Scientific Officer, Exec. VP & Director (Age 55, Pay $706.67k) (LinkedIn Profile)
  • Mr. Ivor Macleod CPA, M.B.A., Chief Financial Officer & Principal Accounting Officer (Age 60, Pay $549.87k) (LinkedIn Profile)
  • Mr. Daniel A. Camardo M.B.A., CEO & Director (Age 53)
  • Ms. Karen Hunady M.S., Director of Corp. Communications & Investor Relations
  • Ms. Alison O'Sullivan M.B.A., Sr. Director of HR
  • Dr. Manal Morsy M.D., PH.D., Sr. VP & Head of Global Regulatory Affairs
  • Dr. Robert Mays Ph.D., VP of Regenerative Medicine & Head of Neuroscience Programs
  • Mr. Rakesh Ramachandran, Head of Information Technology & Communications and VP
  • Ms. Maia Hansen M.B.A., M.S., Sr. VP and Head of Operations & Supply Chain
  • Dr. Eric Jenkins M.D., Sr. Medical Director & Head of Clinical Operations

What is Gil Van Bokkelen's approval rating as Athersys' CEO?

2 employees have rated Athersys CEO Gil Van Bokkelen on Glassdoor.com. Gil Van Bokkelen has an approval rating of 100% among Athersys' employees. This puts Gil Van Bokkelen in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Athersys own?

What is Athersys' stock symbol?

Athersys trades on the NASDAQ under the ticker symbol "ATHX."

How do I buy shares of Athersys?

Shares of ATHX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Athersys' stock price today?

One share of ATHX stock can currently be purchased for approximately $0.25.

How much money does Athersys make?

Athersys (NASDAQ:ATHX) has a market capitalization of $65.38 million and generates $5.51 million in revenue each year. The biopharmaceutical company earns $-86,960,000.00 in net income (profit) each year or ($0.35) on an earnings per share basis.

How many employees does Athersys have?

Athersys employs 104 workers across the globe.

When was Athersys founded?

Athersys was founded in 1995.

How can I contact Athersys?

Athersys' mailing address is 3201 CARNEGIE AVENUE, CLEVELAND OH, 44115. The official website for Athersys is www.athersys.com. The biopharmaceutical company can be reached via phone at (216) 431-9900, via email at ir@athersys.com, or via fax at 216-361-9495.

This page (NASDAQ:ATHX) was last updated on 7/7/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.